Full Breakdown
EU Parliament Votes to Suspend Pharmaceutical Wastewater Obligations Amid Cost Dispute
6/18/2026, 11:35:53 PM
EU Vote to Suspend Pharmaceutical Wastewater Obligations
The European Parliament voted to temporarily suspend the obligations that require the medicines and cosmetics sectors to cover up to 80 % of the costs for additional wastewater-treatment facilities under the Urban Wastewater Treatment Directive. Lawmakers cited growing doubts about the cost assumptions used by the European Commission and warned that the levy could jeopardise the availability of medicines.
Legislative Background and the Urban Wastewater Treatment Directive
The directive implements a polluter-pays principle, termed extended producer responsibility (EPR), which obliges producers of pharmaceuticals and cosmetics to finance a large share of treatment upgrades needed to remove trace contaminants from water. The cost-sharing formula was devised by the European Commission based on its pollutant-load modelling.
Key Figures and Groups
Key actors include EPP MEP Oliver Schenk, the generic medicines lobby, the European Commission, and centre-left MEPs.
Financial Scope of the Wastewater Requirement
The current framework could charge the medicines and cosmetics sectors a large share of capital and operating expenses for new treatment plants. The generic medicines industry argues the Commission’s estimates undervalue true removal costs and that other industrial sectors also contribute to pharmaceutical residues.
Potential Implications for Industry and EU Policy
Temporarily lifting the levy could lower production costs, helping maintain medicine supply and supporting EU strategic autonomy in pharmaceuticals. Critics warn that weakening EPR may reduce incentives for manufacturers to curb emissions, potentially undermining water-quality goals.
Official Statements and Responses
Oliver Schenk said doubts over cost assumptions and medicine availability justify an independent reassessment and a temporary suspension. Centre-left MEPs called for a new study but rejected any permanent suspension of the polluter-pays rule. The European Commission has not issued a comment.
Opposition and Criticism
Centre-left lawmakers decried the suspension, arguing that the EPR framework is essential for ensuring polluters fund remediation and warning that its removal could set a precedent.
Conflicting Views on Cost Modeling
The medicines sector claims the Commission’s pollutant-modeling is flawed, that other sectors share responsibility, and that actual removal costs would far exceed projected figures; no independent study exists yet.
Verbatim Quotes
- “Given the growing doubts surrounding the underlying cost assumptions and the potential impact on the availability of medicines, an independent reassessment and a temporary suspension of the relevant obligations are the right course of action,” — Oliver Schenk, EPP MEP
- “Europe cannot seek to bring pharmaceutical production back with one hand while making it economically less attractive with the other,” — Oliver Schenk, EPP MEP
- “If we want strategic autonomy, we must also create the right framework conditions to achieve it.” — Oliver Schenk, EPP MEP
What’s Next
The resolution mandates an independent assessment of pollutant loads and cost estimates, which will determine whether the suspension remains temporary and whether EU legislation will revise EPR provisions.
